How to buy Codexis stock | $20.5

Codexis, Inc is a biotechnology business based in the US. Codexis shares (CDXS) are listed on the NASDAQ and all prices are listed in US Dollars. Codexis employs 181 staff and has a trailing 12-month revenue of around 0.00.

Codexis stock price (NASDAQ: CDXS)

Use our graph to track the performance of CDXS stocks over time.

Codexis shares at a glance

• Key figures

Information last updated 2021-07-29.

Latest market close	$20.50
52-week range	$11.29 - $29.56
50-day moving average	$21.39
200-day moving average	$22.34
Wall St. target price	$27.88
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.26

Buy Codexis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Codexis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Codexis, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Codexis price performance over time

Historical closes compared with the close of $20.5 from 2021-05-28

1 week (2021-07-19)	N/A
1 month (2021-06-30)	-9.53%
3 months (2021-04-30)	-11.56%
6 months (2021-01-26)	N/A

1 year (2020-07-26)	N/A
2 years (2019-07-26)	N/A
3 years (2018-07-26)	N/A
5 years (2016-07-26)	N/A

Codexis financials

Revenue TTM	$72.4 million
Gross profit TTM	$11.1 million
Return on assets TTM	-8.73%
Return on equity TTM	-19.35%
Profit margin	-35.11%
Book value	$2.54
Market capitalisation	$1.4 billion

TTM: trailing 12 months

Shorting Codexis shares

There are currently 6.7 million Codexis shares held short by investors – that's known as Codexis's "short interest". This figure is 5.5% down from 7.1 million last month.

There are a few different ways that this level of interest in shorting Codexis shares can be evaluated.

Codexis's "short interest ratio" (SIR)

Codexis's "short interest ratio" (SIR) is the quantity of Codexis shares currently shorted divided by the average quantity of Codexis shares traded daily (recently around 411227.21674877). Codexis's SIR currently stands at 16.24. In other words for every 100,000 Codexis shares traded daily on the market, roughly 16240 shares are currently held short.

However Codexis's short interest can also be evaluated against the total number of Codexis shares, or, against the total number of tradable Codexis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Codexis's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Codexis shares in existence, roughly 100 shares are currently held short) or 0.123% of the tradable shares (for every 100,000 tradable Codexis shares, roughly 123 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Codexis.

Find out more about how you can short Codexis stock.

Codexis share dividends

We're not expecting Codexis to pay a dividend over the next 12 months.

Codexis share price volatility

Over the last 12 months, Codexis's shares have ranged in value from as little as $11.29 up to $29.56. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Codexis's is 1.2737. This would suggest that Codexis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Codexis overview

Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients.

Frequently asked questions

What percentage of Codexis is owned by insiders or institutions?
Currently 2.63% of Codexis shares are held by insiders and 100.499% by institutions. How many people work for Codexis?
Latest data suggests 181 work at Codexis. When does the fiscal year end for Codexis?
Codexis's fiscal year ends in December. Where is Codexis based?
Codexis's address is: 200 Penobscot Drive, Redwood City, CA, United States, 94063 What is Codexis's ISIN number?
Codexis's international securities identification number is: US1920051067 What is Codexis's CUSIP number?
Codexis's Committee on Uniform Securities Identification Procedures number is: 192005106